stoxline Quote Chart Rank Option Currency Glossary
Kiromic BioPharma, Inc. (KRBP)
3.46  0.11 (3.28%)    02-23 15:58
Open: 3.48
High: 3.6
Volume: 3,778
Pre. Close: 3.35
Low: 3.3
Market Cap: 4(M)
Technical analysis
2024-02-23 4:37:49 PM
Short term     
Mid term     
Targets 6-month :  4.41 1-year :  5.15
Resists First :  3.77 Second :  4.41
Pivot price 2.33
Supports First :  2.21 Second :  1.25
MAs MA(5) :  3.23 MA(20) :  2.1
MA(100) :  0.88 MA(250) :  2.2
MACD MACD :  0.5 Signal :  0.3
%K %D K(14,3) :  84.9 D(3) :  79.2
RSI RSI(14): 73.8
52-week High :  8.97 Low :  0.15
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ KRBP ] has closed below upper band by 15.2%. Bollinger Bands are 307.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.6 - 3.62 3.62 - 3.64
Low: 3.26 - 3.28 3.28 - 3.29
Close: 3.43 - 3.46 3.46 - 3.49
Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Headline News

Wed, 14 Feb 2024
Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months - Business Wire

Fri, 05 Jan 2024
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 ... - Business Wire

Thu, 14 Dec 2023
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non ... - Yahoo Finance

Thu, 16 Nov 2023
Kiromic BioPharma Announces Uplisting to OTCQB Market - Business Wire

Wed, 13 Sep 2023
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14 - Yahoo Finance

Thu, 16 Feb 2023
Kiromic BioPharma CEO Issues Letter to Stockholders - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 8.2 (%)
Held by Institutions 20.4 (%)
Shares Short 46 (K)
Shares Short P.Month 62 (K)
Stock Financials
EPS -19.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.82
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -98.9 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -15.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -0.18
PEG Ratio 0
Price to Book value -0.91
Price to Sales 0
Price to Cash Flow -0.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android